Table 1.
Patient and tumor characteristics
| Characteristic | HDRB group (n = 98) | SBRT group (n = 51) |
|---|---|---|
| Pretreatment PSA (ng/dL) | 42.2 (4.1–189.0) | 40.3 (5.6–303.0) |
| <10 | 14 (14.3) | 8 (15.6) |
| 10–20 | 28 (28.6) | 14 (27.5) |
| >20 | 56 (57.1) | 29 (56.9) |
| Gleason score | ||
| ≤7 | 51 (52) | 27 (52.9) |
| 8 | 39 (39.8) | 18 (35.3) |
| 9–10 | 8 (8.2) | 6 (11.8) |
| Clinical stage | ||
| ≤T2c | 18 (18.4) | 18 (35.3) |
| T3a | 30 (30.6) | 8 (15.7) |
| T3b | 50 (51) | 23 (45.1) |
| T4 | - | 2 (3.9) |
| Lymph node status (clinical) | ||
| N+ | 32 (32.7) | 15 (29.4) |
| N- | 66 (67.3) | 36 (70.6) |
| Technique for pelvic lymph node irradiation | ||
| VMAT (Gy) | 18 | 38 |
| 48.6 (45.4–50.2) | 47.1 (44.9–50.6) | |
| 3D-CRT (Gy) | 80 | 13 |
| 47.9 (43.2–50.8) | 49.6 (42.8–50.2) |
Values are presented as number (%) or mean (min–max).
HDRB, high dose rate brachytherapy; SBRT, stereotactic body radiotherapy; PSA, prostate-specific antigen level; VMAT, volumetric modulated arc therapy; RT, radiotherapy; 3D-CRT, Three-dimensional conformal radiotherapy.